Wheaton Science Products
New 96-well 3D Tissue Model Production System for Cell-based Screening Previews on TAP Biosystems Booth 1107 at the SBS
By: TAP Biosystems Published: March 31 2011
Cambridge, UK: TAP Biosystems, (formerly The Automation Partnership), the leading supplier of innovative automation and consumables for life science applications today announced it is introducing a 96-well version of its RAFT™ (Real Architecture for 3D Tissue™) system for the generation of consistent multi-cellular 3D tissue models on Booth 1107 at the Society of Biomolecular Screening (SBS) Conference.
TAP Biosystems’ specialists will be on the booth to explain how the 96-well version of the award winning RAFT System can produce realistic 3D tissue models using a wide range of cell types and cell seeding densities, as well as co-cultured layers of different cell types. They will also discuss why the transparent tissue models generated would be ideal for improving cell-based secondary screening applications using standard analytical techniques including light or confocal microscopy, fluorescence, histology and transcriptomic assays.
The RAFT System is based on a novel, patented process using collagen to mimic closely an in vivo environment. The system combines workstation, consumables and reagents to allow multi-cellular 3D tissue models to be made rapidly and consistently in standard plate formats. The RAFT System range now includes 12, 24 and 96 well plates and a 24 well system with permeable membrane inserts for barrier assays.
Dr Grant Cameron, TAP Biosystems’ RAFT Development Director stated: “There is an increasing drive in drug discovery and cell based screening to provide cells with a more realistic cellular environment which will lead to more physiological cellular responses.
Cameron added: “Our 96-well RAFT System is capable of delivering collagen based tissue strength models and we are excited to preview this emerging and adaptable technology at the world’s leading screening show. RAFT will interest progressive scientists requiring easy access to a wide range of 3D tissue models and we look forward to discussing how they could incorporate RAFT into their cell based screening programmes.”